ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BeOne Medicines AG (ONC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong revenue growth, positive analyst sentiment, and a promising outlook for its key product, Brukinsa. Despite short-term technical weakness, the long-term fundamentals and growth trajectory make it a suitable investment.
The stock is currently oversold with an RSI of 15.388, indicating potential for a rebound. However, the MACD histogram is negative (-7.898) and expanding downward, signaling bearish momentum. The stock is trading near its support level (S1: 299.198), which could provide a potential entry point. Moving averages are converging, suggesting indecision in the market.
Strong Q4 2025 revenue growth of 33% QoQ and 41% YoY.
Brukinsa revenue increased by 38% QoQ and 49% YoY, solidifying its market position.
Analysts raised price targets across the board, with targets now ranging from $405 to $425, reflecting confidence in the company's growth trajectory.
Fiscal 2026 revenue guidance aligns with consensus, showcasing stability.
Hedge funds are aggressively selling, with a 7307.41% increase in selling activity over the last quarter.
The MACD and options data indicate short-term bearish sentiment.
Net income and EPS have significantly declined YoY, which may concern some investors.
In Q4 2025, the company reported $1.5 billion in revenue, a 33% QoQ increase, and projected $5.3 billion for 2026. Brukinsa contributed $1.1 billion in Q4 revenue, up 38% QoQ. However, net income dropped by -202.88% YoY, and EPS fell by -188.89% YoY, indicating profitability challenges despite strong revenue growth.
Analysts are overwhelmingly positive on ONC, with multiple firms raising their price targets post-Q4 results. Guggenheim, RBC Capital, Truist, and Barclays have all increased their targets, with the highest being $425. Analysts highlight strong growth for Brukinsa and long-term pipeline opportunities as key drivers for the stock.
